About Alpha-2A adrenergic receptor
Alpha-2A adrenergic receptor (ADRA2A) is a protein
from Homo sapiens identified by UniProt accession
P08913, 465 residues long.
MolForge cross-references it against 0 known binders and
565 disease associations.
Target properties
| Protein name | Alpha-2A adrenergic receptor |
| UniProt accession | P08913 |
| Gene | ADRA2A |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (565)
Diseases linked to this target (Open Targets).
- attention deficit hyperactivity disorder · score 0.61
- unipolar depression · score 0.61
- pain · score 0.61
- Nasal congestion · score 0.60
- hypotension · score 0.60
- seasonal allergic rhinitis · score 0.60
- hypertension · score 0.60
- delirium · score 0.60
- asthma · score 0.60
- Sepsis · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P08913-F1 | alphafold | PREDICTED | 70.18 | — |
Amino-acid sequence (465 residues)
MFRQEQPLAE GSFAPMGSLQ PDAGNASWNG TEAPGGGARA TPYSLQVTLT LVCLAGLLML LTVFGNVLVI IAVFTSRALK APQNLFLVSL ASADILVATL VIPFSLANEV MGYWYFGKAW CEIYLALDVL FCTSSIVHLC AISLDRYWSI TQAIEYNLKR TPRRIKAIII TVWVISAVIS FPPLISIEKK GGGGGPQPAE PRCEINDQKW YVISSCIGSF FAPCLIMILV YVRIYQIAKR RTRVPPSRRG PDAVAAPPGG TERRPNGLGP ERSAGPGGAE AEPLPTQLNG APGEPAPAGP RDTDALDLEE SSSSDHAERP PGPRRPERGP RGKGKARASQ VKPGDSLPRR GPGATGIGTP AAGPGEERVG AAKASRWRGR QNREKRFTFV LAVVIGVFVV CWFPFFFTYT LTAVGCSVPR TLFKFFFWFG YCNSSLNPVI YTIFNHDFRR AFKKILCRGD RKRIV
Explore Alpha-2A adrenergic receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets